Protein PR73 3'-endogenous Antibody

What are the main p73 isoforms and how are they structurally different?

p73 exists in multiple isoforms, with the two main N-terminal variants being transcriptionally active TAp73 (containing the transactivation domain) and the dominant negative ΔNp73/ΔTAp73 (lacking the transactivation domain). These isoforms arise through two distinct promoters in the TP73 gene - the P1 promoter generates TAp73 transcripts, while the P2 promoter (in exon 3') produces ΔNp73 . Additional complexity arises from alternative splicing at both the 3'-end (generating α, β, γ variants) and the 5'-end (creating Δ2, Δ3, and Δ2-3 variants), resulting in at least 14 different transcripts .

What is the tissue distribution pattern of p73 isoforms?

TAp73 serves as a marker for multiciliated epithelial cells, while ΔTAp73 marks non-proliferative basal/reserve cells in squamous epithelia . p73α has been observed in basal cells of columnar epithelium in the larynx and upper bronchi, transitional epithelium of the bladder, glandular epithelial cells in breast and prostate, and in spermatogonia . Moderate p73α staining has also been found in the parotid gland and occasional colon cells . Interestingly, some mouse tissues show higher levels of ΔNp73, suggesting this isoform may have physiological roles in these specific tissues .

How do p73 isoform expression patterns differ between normal and cancer cells?

Research has shown that the transcriptionally competent TAp73 isoform is abundantly expressed in cancer cell lines compared to the dominant negative ΔNp73 isoform . This finding is significant because, unlike p53, p73 mutations are extremely rare in cancers. Instead, the pro-apoptotic activities of transcriptionally active p73 isoforms are commonly inhibited by over-expression of the dominant negative p73 isoforms . The relative ratio between these isoforms is therefore critical for determining cellular responses to chemotherapeutic agents.

What challenges exist in developing isoform-specific antibodies for p73?

Developing specific antibodies for p73 isoforms presents several significant challenges. First, there is considerable sequence homology between p73 and other p53 family members, leading to cross-reactivity where "most p73 antibodies also bind to p63 or show non-specific binding to proteins outside the p53 family" and "the majority of monoclonal antibodies developed against p63 also cross-react with p73" . Second, discriminating between closely related isoforms requires targeting unique epitopes that may be small or conformationally sensitive. Third, ΔTAp73 isoforms formed by alternative translation initiation at the ATG within exon 4 lack unique N-terminal amino acid sequences, making it particularly difficult to produce antibodies specific for these variants .

How can researchers validate the specificity of p73 isoform antibodies?

Proper validation requires a multi-technique approach. First, perform Western blotting using recombinant proteins of each p73 isoform alongside other p53 family members to confirm specificity. Second, use both reducing and non-reducing conditions to evaluate antibody performance under different protein conformations . Third, employ immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) cells expressing specific isoforms to validate antibody performance in fixed tissues . Fourth, conduct negative control experiments using tissues or cells known not to express the target isoform. Finally, use a combination of antibodies (e.g., p73α positivity with negative TAp73 staining) to indirectly identify the presence of specific variants such as ΔTAp73 .

What methods are most effective for detecting endogenous p73 in biological samples?

For detecting endogenous p73 in biological samples, several approaches have proven effective. Immunoblotting with highly specific antibodies can detect p73 isoforms at nanogram levels in both reducing and non-reducing conditions . Immunofluorescent staining enables visualization of cellular localization patterns, while flow cytometry (FACS analysis) allows quantification across cell populations . For tissue samples, immunohistochemistry with isoform-specific antibodies provides insights into distribution patterns . When studying p73 modifications, immunoprecipitation protocols can be optimized using properly validated antibodies coupled to appropriate beads or resins . For maximum specificity, a combination approach using multiple detection methods and antibodies targeting different epitopes will provide the most reliable results.

How should researchers approach p73 immunoprecipitation experiments?

Immunoprecipitation (IP) of p73 requires careful optimization. Begin by selecting antibodies validated for IP applications with confirmed specificity for your target isoform. Traditional column affinity chromatography approaches can be adapted, using porous resin (typically beaded agarose) with immobilized p73-specific antibodies . When investigating p73's interactions with E3 ligases or other binding partners, consider that different domains of p73 interact with different partners (as shown in Table 1 ), so antibody selection should avoid epitopes that might block key interaction sites. Additionally, when studying post-translational modifications, it's crucial to include appropriate protease and phosphatase inhibitors to preserve the modified state during lysis and immunoprecipitation procedures.

What are the key post-translational modifications that regulate p73 function?

p73 is extensively regulated through post-translational modifications, with ubiquitination, phosphorylation, and acetylation playing critical roles.

For ubiquitination, multiple E3 ligases target p73 isoforms through distinct interaction sites and mechanisms. Itch binds the PY motif (Met 452–Ala 489) of p73α, leading to proteasome-dependent degradation . MDM2 inhibits p73α activity without promoting degradation, while for p73β, it binds specifically to two residues (F15 and W19) . Pirh2 interacts with the DNA-binding domain of both p73α and p73β, promoting ubiquitination via K11-, K29-, K48-, and K63-linked chains .

Phosphorylation occurs through multiple kinases: c-Abl phosphorylates p73 in response to DNA damage, requiring the prolyl isomerase Pin1, which promotes conformational changes leading to enhanced acetylation by p300 . Plk3 phosphorylates p73α at its NH2-terminal region (amino acids 63–113), inhibiting its pro-apoptotic activity, while Plk2 phosphorylates p73 at Ser48 in the TA domain .

Acetylation by p300 enhances p73 stability and pro-apoptotic function, especially in response to DNA-damaging agents. This process is stimulated by YAP1 binding to the p73/p300 complex .

How do ubiquitination patterns affect p73 stability and function?

Ubiquitination of p73 occurs through multiple E3 ligases with distinct effects on stability and function, as outlined in Table 1 . Some E3 ligases, like Itch, promote proteasome-dependent degradation of p73 by targeting its PY motif, while others like MDM2 can inhibit p73 activity without affecting stability . Specific ubiquitination patterns determine the functional outcome - the Cul4A–DDB1 complex causes monoubiquitination that inhibits p73 transcriptional activity without affecting stability, while UFD2a mediates ubiquitination-independent degradation .

The ubiquitination-deubiquitination balance is regulated by several factors: DNA-damaging agents (doxorubicin, cisplatin, etoposide) decrease endogenous Itch expression, leading to increased p73 levels and enhanced apoptosis . Yes-associated protein 1 (Yap1) competes with Itch for binding to p73, preventing Itch-mediated ubiquitination and degradation . Similarly, Nedd4-binding partner-1 (N4BP1) competes with Itch for binding to p73α, reducing its ubiquitylation . These complex interactions create a regulatory network that fine-tunes p73 stability and activity based on cellular context and stress conditions.

How can researchers distinguish between the effects of different p73 isoforms in functional studies?

To distinguish between effects of different p73 isoforms, employ a multi-faceted approach:

• Isoform-specific knockdown/knockout: Use siRNA or CRISPR-Cas9 targeting unique regions of each isoform. For instance, target the unique N-terminal sequence of TAp73 or the alternative first exon of ΔNp73.

• Isoform ratio analysis: Since the TAp73:ΔNp73 ratio is critical for determining cellular outcomes, quantify this ratio using RT-qPCR primers specific to each variant . Carefully design primers to distinguish between closely related transcripts.

• Complementation studies: After knockdown of endogenous p73, reintroduce specific isoforms individually to identify their distinct functions.

• Transcriptomic profiling: Compare gene expression changes induced by different isoforms to identify isoform-specific target genes.

• Domain-specific antibodies: Use antibodies targeting the TA domain (for TAp73) or the unique N-terminal region of ΔNp73, combined with antibodies to C-terminal domains (like the SAM domain in p73α) to distinguish between combinations of N- and C-terminal variants .

• Functional readouts: Monitor apoptosis, cell cycle arrest, and differentiation markers to correlate with expression patterns of specific isoforms.

What approaches can overcome the limitations in detecting low-abundance p73 isoforms?

Detecting low-abundance p73 isoforms requires specialized strategies:

• Enrichment techniques: Use immunoprecipitation with highly specific antibodies before detection to concentrate the target protein .

• Ultra-sensitive PCR methods: Studies investigating ΔNp73 and other p73 N-terminal isoforms have employed highly sensitive PCR methods capable of identifying extremely low mRNA levels (approximately 10 copies in an entire sample reaction, equivalent to less than 1 copy/100 cells) .

• Enhanced immunodetection: For protein detection, use signal amplification systems like tyramide signal amplification or polymer-based detection systems to enhance sensitivity for immunohistochemistry.

• Cellular fractionation: Isolate nuclear fractions where transcription factors typically concentrate to increase the relative abundance of p73 isoforms.

• Protein stabilization: Treat samples with proteasome inhibitors (e.g., MG132) to prevent degradation of unstable isoforms, potentially increasing their detectability .

• Mass spectrometry: For unbiased detection, employ targeted mass spectrometry approaches with heavy-labeled peptide standards corresponding to unique regions of each isoform.

How do alterations in p73 isoform expression contribute to cancer progression?

The balance between TAp73 (tumor suppressive) and ΔNp73 (oncogenic) isoforms is critical in cancer progression. Unlike p53, p73 mutations are extremely rare in cancers. Instead, the pro-apoptotic activities of transcriptionally active p73 isoforms are commonly inhibited by over-expression of dominant negative p73 isoforms .

In p53-null cancer contexts, p73 becomes particularly important. For example, in leukemia cell lines lacking active p53, treatments that increase TAp73α expression while decreasing ΔNp73 can induce apoptosis . The combination of arsenic trioxide and MEK1 inhibitors synergistically increases TAp73α expression and its acetylation by p300, enhancing recruitment to pro-apoptotic gene promoters .